Search

Type-2 diabetes (T2D) is a rapidly growing multifactorial metabolic disorder that induces the onset of various diseases in the human body. The compositional and metabolic shift of the gut microbiota is a crucial factor behind T2D. Hence, gaining insight into the metabolic profile of the gut microbiota is essential for revealing their role in regulating the metabolism of T2D patients. Here, we have focused on the genome-scale community metabolic model reconstruction of crucial T2D-associated gut microbes. The model-based analysis of biochemical flux in T2D and healthy gut conditions showed distinct biochemical signatures and diverse metabolic interactions in the microbial community. The metabolic interactions encompass cross-feeding of short-chain fatty acids, amino acids, and vitamins among individual microbes within the community. In T2D conditions, a reduction in the metabolic flux of acetate, butyrate, vitamin B5, and bicarbonate was observed in the microbial community model, which can impact carbohydrate metabolism. The decline in butyrate levels is correlated with both insulin resistance and diminished glucose metabolism in T2D patients. Compared to the healthy gut, an overall reduction in glucose consumption and SCFA production flux was estimated in the T2D gut environment. Moreover, the decreased consumption profiles of branch chain amino acids (BCAAs) and aromatic amino acids (AAAs) in the T2D gut microbiota can be a distinct biomarker for T2D. Hence, the flux-level analysis of the microbial community model can provide insights into the metabolic reprogramming in diabetic gut microbiomes, which may be helpful in personalized therapeutics and diet design against T2D. [ABSTRACT FROM AUTHOR]

Copyright of Jordan Journal of Pharmaceutical Sciences is the property of University of Jordan and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The project work was designed to investigate the phytochemical and selected pharmacological activities (antidiarrheal, analgesic, neuropharmacological behavior and anthelmintic) of leaves of Sanchezia nobilis. Hook. F. (Family: Acanthaceae). From its phytochemical analysis we found the presence of reducing sugar, combined reducing sugar, phenolic compounds, tannins, flavonoids, carbohydrates, gums, steroids, alkaloids, glycosides and terpenoids. In vivo antidiarrheal activity was substantiated by prolongation of latent period and decrease in total number of stools. The extract produced 62.49% and 74.01% decrease in stool count at the doses of 250 and 500 mg/kg body weight respectively while the standard drug Loperamide decrease in stool count was found to be 87.05% at a dose of 3 mg/kg body weight. The leaves extract produced 32.7% and 41.78% inhibition of writhing at the doses of 250 mg/kg and 500 mg/kg body weight respectively while the standard drug Diclofenac Na was found to be 74.23% at a dose of 25 mg/kg body weight. The extract showed dose dependent CNS depressant activity by reducing the locomotors activity. Higher dose of this extract (500 mg/kg body weight) comparing with standard Diazepam exposed sedative effect potentially. The extract exhibited concentration dependent anthelmintic activity against Paramphistomum cervi using Albendazole (15 mg/mL) as standard. The paralysis occurred between 9.00 to 83.91 min and death occurred between 11.33 to 86.33 min which were comparable to standard drug Albendazole. So, the present study concluded that the extract is fortified with significant antidiarrheal, CNS depression and anthelmintic activity and moderate analgesic activity. [ABSTRACT FROM AUTHOR]